Pandemic Preparedness: The Potential Advantage of Medicines That Prevent Acute Side Effects of Vaccination, SARS-CoV-2 as an Example

Future Pharmacology Pub Date : 2022-08-01 DOI:10.3390/futurepharmacol2030019

P. Kiani, J. Balikji, J. Garssen, J. Verster

{"title":"Pandemic Preparedness: The Potential Advantage of Medicines That Prevent Acute Side Effects of Vaccination, SARS-CoV-2 as an Example","authors":"P. Kiani, J. Balikji, J. Garssen, J. Verster","doi":"10.3390/futurepharmacol2030019","DOIUrl":null,"url":null,"abstract":"Vaccination against SARS-CoV-2 is an important and essential strategy to combat the 2019 coronavirus disease (COVID-19) pandemic. Vaccination has shown to be effective in reducing the spread of SARS-CoV-2, reducing the chances of becoming infected and developing severe COVID-19, and reducing hospitalization and mortality rates. However, the vaccinations against SARS-CoV-2 are accompanied by undesirable side effects which may be in part responsible for a reduction in the willingness to become vaccinated. At this moment (June 2022), 24.3% of the US adult population (18+ years old) is not fully vaccinated against SARS-CoV-2, and 49.5% did not receive their follow-up booster vaccination. The most important motives for refusing vaccination are the unknown long-term side effects and the known acute side effects of vaccination. Here, we discuss the importance of recognizing the impact of this reactogenicity on individuals’ willingness to vaccinate and how the development of effective and safe medicines that prevent or mitigate the unwanted side effects of the vaccination may help to increase the willingness to vaccinate.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/futurepharmacol2030019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Vaccination against SARS-CoV-2 is an important and essential strategy to combat the 2019 coronavirus disease (COVID-19) pandemic. Vaccination has shown to be effective in reducing the spread of SARS-CoV-2, reducing the chances of becoming infected and developing severe COVID-19, and reducing hospitalization and mortality rates. However, the vaccinations against SARS-CoV-2 are accompanied by undesirable side effects which may be in part responsible for a reduction in the willingness to become vaccinated. At this moment (June 2022), 24.3% of the US adult population (18+ years old) is not fully vaccinated against SARS-CoV-2, and 49.5% did not receive their follow-up booster vaccination. The most important motives for refusing vaccination are the unknown long-term side effects and the known acute side effects of vaccination. Here, we discuss the importance of recognizing the impact of this reactogenicity on individuals’ willingness to vaccinate and how the development of effective and safe medicines that prevent or mitigate the unwanted side effects of the vaccination may help to increase the willingness to vaccinate.

查看原文本刊更多论文

大流行防范:预防疫苗急性副作用的药物的潜在优势，以SARS-CoV-2为例

针对SARS-CoV-2的疫苗接种是抗击2019年冠状病毒病(COVID-19)大流行的重要和必要战略。疫苗接种已被证明可有效减少SARS-CoV-2的传播，减少感染和发展为严重COVID-19的机会，并降低住院率和死亡率。然而，针对SARS-CoV-2的疫苗接种伴随着不良副作用，这可能是降低接种疫苗意愿的部分原因。目前(2022年6月)，24.3%的美国成年人(18岁以上)没有完全接种SARS-CoV-2疫苗，49.5%没有接受后续加强疫苗接种。拒绝接种疫苗的最重要动机是未知的长期副作用和已知的急性副作用。在这里，我们讨论了认识到这种反应原性对个体接种意愿的影响的重要性，以及如何开发有效和安全的药物来预防或减轻疫苗接种的不良副作用，可能有助于提高疫苗接种意愿。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Pharmacology

自引率

0.00%

发文量